Effectiveness and Safety of Tasso+ Pediatric Microsampling for Child Blood Lead Levels: Cohort Study.
7 affiliations
- 1Department of Health, Society, and Behavior, Joe C. Wen School of Population & Public Health, University of California, Irvine, 856 Health Sciences Quad, Office 3555, Irvine, CA, 92697, United States, 1 949-824-5242, 1 949-824-1019.
- 2Department of Chicano/Latino Studies, School of Social Sciences, University of California, Irvine, Irvine, CA, United States.
- 3Institute of Interdisciplinary Salivary Bioscience Research, University of California, Irvine, Irvine, CA, United States.
- 4Center for the Neurobiology of Learning and Memory (CNLM), University of California, Irvine, Irvine, CA, United States.
- 5Community Member At-Large, Santa Ana, CA, United States.
- 6Orange County Environmental Justice, Santa Ana, CA, United States.
- 7Department of Environmental and Occupational Health, Joe C. Wen School of Population & Public Health, University of California, Irvine, Irvine, CA, United States.
Abstract
Background
The growing interest in promoting child health requires minimally invasive biospecimen collection. Particularly during and since the COVID-19 pandemic, there has been increased interest in microsampling technology to democratize participation in research involving biospecimens, particularly for children. These advances mitigate barriers, such as scheduling, transportation, and psychosocial challenges. Tasso is a microsampling biomedical device that has gained popularity in research. It uses a vacuum-assisted capillary system that attaches to the upper arm and is considered minimally invasive, as it requires no venipuncture or phlebotomist. Yet, important gaps remain in understanding Tasso performance, particularly among pediatric populations where its administration is limited.Objective
This research addresses a significant gap in biomedical device development by examining the effectiveness, safety, and failure rate of the Tasso+ Class II medical device designed for blood sampling (puncture) among children. The Tasso+ was selected for a pediatric cohort research study given advertisement of methodological advantages over traditional phlebotomy. This original investigation characterizes the effectiveness of and potential for institutional review board-designated adverse events, following the use of the Tasso+ Class II medical device within a pediatric population.Methods
Blood collection was essential to measure lead (Pb) exposures for children residing in a region known to be polluted. Parents/guardians consented, and children assented to Tasso+ sampling on the upper arm. The Tasso+ device was administered in 2024 by trained researchers on 2 pilot participants (ages 7-8 years) and subsequently 13 study participants (ages 7-10 years). Sampling was terminated upon participant reports of persistent pain and scarring on children's arms. Follow-up was conducted at intervals after device application: 2-11 weeks and 10-19 months. Data sources included data collection and laboratory records and survey-based follow-up with participating families. Analyses involved descriptive statistics drawn from data collection and laboratory records and descriptive statistics and content analysis of a follow-up survey administered to participating families. Content analysis of open-ended responses to the follow-up survey administered to families identified themes and their frequency of occurrence. Main measures included the device failure rate, effectiveness (ie, blood volume), and adverse outcomes at the arm puncture site.Results
The device failure rate was 26.7% (4/15), with only 66.7% (10/15) and 20% (3/20) of the cases having the optimal (>450 µL) or adequate (250-449 µL) blood volume, respectively. At initial follow-up, 23.1% reported ongoing pain; none reported ongoing pain at extended follow-up. Scarring showed high initial incidence (61.5%) and persistence (75.0%). Children reported shame related to the participant-reported and researcher-observed scar and impacts of pain on feelings toward physical touch (eg, hug/embrace).Conclusions
These effectiveness barriers and adverse events highlight the need for documentation to inform the future rollout of novel devices for participatory research, longer-term follow-up, and addressing potential gaps in transparency between manufacturers and researchers who use biomedical devices.
Related
- Effectiveness and Safety of Suction-Assisted Technologies in Pediatric Endourological Stone Surgery: A Systematic Review by the EAU-YAU Pediatric Urology Working Group.
- Real-world efficacy and safety of blinatumomab across three clinical settings in pediatric B-cell acute lymphoblastic leukemia: a single-center retrospective cohort study
- Safety and surgical outcomes of sodium fluorescein-guided pediatric brain tumor surgery: a retrospective before-and-after single-center cohort study
- Safety & Effectiveness of Mifepristone for Medication Abortion in a National Claims Cohort, 2017-2023
- Comparative Effectiveness and Hematological Safety of Linezolid and Tedizolid in Bone and Joint Infections: A Retrospective Cohort Study
BibTeX
@article{lebron2026effectiveness,
title = {{Effectiveness and Safety of Tasso+ Pediatric Microsampling for Child Blood Lead Levels: Cohort Study.}},
author = {Alana M W LeBron and Kristina Uban and Julia Mangione and Olaya Daki and Erika Ramirez-Mayoral and Maya Cheav and Sarahi Gutierrez Luna and Adriana Orellana and Yohana Rojas de Jesus and Yezenia Marrujo and Blanca I Contreras and Teresa Campos and Jun Wu},
journal = {JMIR formative research},
year = {2026},
month = oct,
doi = {10.2196/101700},
url = {https://europepmc.org/article/MED/42953969},
note = {CC BY},
}
RIS
TY - JOUR
TI - Effectiveness and Safety of Tasso+ Pediatric Microsampling for Child Blood Lead Levels: Cohort Study.
AU - Alana M W LeBron
AU - Kristina Uban
AU - Julia Mangione
AU - Olaya Daki
AU - Erika Ramirez-Mayoral
AU - Maya Cheav
AU - Sarahi Gutierrez Luna
AU - Adriana Orellana
AU - Yohana Rojas de Jesus
AU - Yezenia Marrujo
AU - Blanca I Contreras
AU - Teresa Campos
AU - Jun Wu
PY - 2026
DA - 2026/10/22
JO - JMIR formative research
DO - 10.2196/101700
UR - https://europepmc.org/article/MED/42953969
AB - Background The growing interest in promoting child health requires minimally invasive biospecimen collection. Particularly during and since the COVID-19 pandemic, there has been increased interest in microsampling technology to democratize participation in research involving biospecimens, particularly for children. These advances mitigate barriers, such as scheduling, transportation, and psychosocial challenges. Tasso is a microsampling biomedical device that has gained popularity in research. It uses a vacuum-assisted capillary system that attaches to the upper arm and is considered minimally invasive, as it requires no venipuncture or phlebotomist. Yet, important gaps remain in understanding Tasso performance, particularly among pediatric populations where its administration is limited.Objective This research addresses a significant gap in biomedical device development by examining the effectiveness, safety, and failure rate of the Tasso+ Class II medical device designed for blood sampling (puncture) among children. The Tasso+ was selected for a pediatric cohort research study given advertisement of methodological advantages over traditional phlebotomy. This original investigation characterizes the effectiveness of and potential for institutional review board-designated adverse events, following the use of the Tasso+ Class II medical device within a pediatric population.Methods Blood collection was essential to measure lead (Pb) exposures for children residing in a region known to be polluted. Parents/guardians consented, and children assented to Tasso+ sampling on the upper arm. The Tasso+ device was administered in 2024 by trained researchers on 2 pilot participants (ages 7-8 years) and subsequently 13 study participants (ages 7-10 years). Sampling was terminated upon participant reports of persistent pain and scarring on children's arms. Follow-up was conducted at intervals after device application: 2-11 weeks and 10-19 months. Data sources included data collection and laboratory records and survey-based follow-up with participating families. Analyses involved descriptive statistics drawn from data collection and laboratory records and descriptive statistics and content analysis of a follow-up survey administered to participating families. Content analysis of open-ended responses to the follow-up survey administered to families identified themes and their frequency of occurrence. Main measures included the device failure rate, effectiveness (ie, blood volume), and adverse outcomes at the arm puncture site.Results The device failure rate was 26.7% (4/15), with only 66.7% (10/15) and 20% (3/20) of the cases having the optimal (>450 µL) or adequate (250-449 µL) blood volume, respectively. At initial follow-up, 23.1% reported ongoing pain; none reported ongoing pain at extended follow-up. Scarring showed high initial incidence (61.5%) and persistence (75.0%). Children reported shame related to the participant-reported and researcher-observed scar and impacts of pain on feelings toward physical touch (eg, hug/embrace).Conclusions These effectiveness barriers and adverse events highlight the need for documentation to inform the future rollout of novel devices for participatory research, longer-term follow-up, and addressing potential gaps in transparency between manufacturers and researchers who use biomedical devices.
SN - 2561-326X
ER -